- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT03018093
A Phase I Study Evaluating Safety and Efficacy of C-CAR011 Treatment in Adult Subjects With r/r CD19+B-ALL
A Phase I Study Evaluating Safety and Efficacy of CBM.CD19-targeted Chimeric Antigen Receptor T Cells (C-CAR011) Treatment in Adult Subjects With Relapsed/Refractory CD19+ B Cells Acute Lymphoblastic Leukemia(CALL-1)
Panoramica dello studio
Stato
Intervento / Trattamento
Descrizione dettagliata
This is a single-center, Open Label phase I clinical trial, 20 subjects planned to be enrolled. The trial have two stages (Phase I dose-escalation clinical trial and phase I dose expansion trial).Subjects will be divided into low-dose group, medium-dose group and high-dose group.Additional patients will be enrolled to confirm the optimal dose
Dose CAR+ cells/kg Low 0.5×106 Medium 1.5×106 High 3.0×106
Tipo di studio
Iscrizione (Anticipato)
Fase
- Fase 1
Contatti e Sedi
Luoghi di studio
-
-
Beijing
-
Beijing Shi, Beijing, Cina
- Reclutamento
- Chinese PLA General Hospital
-
Contatto:
- Li Yu
- Numero di telefono: 010-66937644
- Email: liyu301@vip.163.com
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Age 14-75 years old, male or female.
- Volunteered to participate in this study and signed written informed consent form.
- Histologically diagnosed as CD19+B-ALL according to the NCCN Acute Lymphoblastic Leukemia Clinical Practice Guidelines (2016 version 1).
Relapsed or refractory CD19+B-ALL (meet one of the following conditions)
- Refractory as defined not achieving a CR(complete remission, morphology<5% blasts) after two cycles of standard chemotherapy regimen.
- Duration of remission ≤ 12 months after the first induction chemotherapy regimen.
- Refractory disease after one or more salvage therapies.
- Two or more Bone Marrow relapse.
- Morphological disease in the bone marrow (≥ 5% blasts).
- Subjects with Philadelphia chromosome negative(Ph-) disease, or subjects with Philadelphia chromosome positive(Ph+) disease that are intolerant to or have failed 2 lines of tyrosine kinase inhibitor therapy (TKI), or if TKI therapy is contraindicated are eligible.
- No salvage chemotherapy therapy within 4 weeks prior to C-CAR011 therapy.
- No immunosuppressant(including but not limited to systemic corticosteroid therapy) within 4 weeks prior to C-CAR011 therapy.
- No antibody therapy within 4 weeks prior to C-CAR011 therapy.
- Normal cardiac function confirmed by ECHO with left ventricular ejection fraction (LVEF) ≧ 50%, no evidence of pericardial effusion and clinically significant arrhythmias.
- Baseline oxygen saturation ≧ 92% on room air and with normal pulmonary function, no evidence of active lung infection.
- No contraindications of peripheral blood apheresis.
- Expected survival ≧ 3 months.
- Eastern cooperative oncology group (ECOG) performance status of 0 or 1.
Exclusion Criteria:
- History of severe allergic disease or allergic to one or more drugs.
- Any kind of these laboratory testing: serum total bilirubin≧1.5mg/dl, serum albumin≦35g/L, ALT, AST≧2.5×ULN, serum creatinine≧2.0mg/dl, platelets≦50×109/L.
- Extramedullary disease.
- Relapsed disease after allogeneic hematopoietic stem cell transplantation.
- Diagnosis of Burkitt's leukemia/lymphoma according to WHO classification or chronic myelogenous leukemia lymphoid blast crisis.
- Subjects with concomitant genetic syndrome such as Fanconi anemia, Kostmann syndrome, Shwachman-Diamond syndrome or any other known bone marrow failure syndrome.
- Subjects with grade III or above severe hypertension(WHO/ISH Guidelines for the Management of Hypertension, 1999).
- History of myocardial infarction, cardiac angioplasty or stenting, unstable angina, or other clinically significant cardiac disease within 12 months prior to enrollment.
- Subjects with class III and IV heart failure according to the NYHA Heart Failure Classifications;
- History of QT prolongation with clinically significant arrhythmias.
- History of epilepsy or other central nervous system disorders.
- History or presence of any central nervous system leukemia(CNS3, CNS4) disorder , with insensitive to intrathecal injection of or radiotherapy of head/spine; but effectively controlled cases will be eligible.
- Autoimmune diseases needing treatment, or immune deficiency or other diseases needing immunosuppressive therapy.
- Subjects with TKIs therapy (Ph+ ALL) within 1 week prior to enrollment.
- Severe active infection (uncomplicated urinary tract infections, bacterial pharyngitis allowed) or currently receiving intravenous antibiotic therapy and has received intravenous antibiotic therapy within one week. Prophylactic antibiotic, antiviral and antifungal treatment is permissible.
- Used any genetically modified T cell therapy.
- Presence of any indwelling line or drain (e.g., percutaneous nephrostomy tube, indwelling Foley catheter, biliary drain, or pleural/peritoneal/pericardial catheter). Ommaya reservoirs and dedicated central venous access catheters such as a Port-a-Cath or Hickman catheter are permitted.
- Live vaccine≦4 weeks prior to enrollment.
- Known infection with HIV, TB, hepatitis B (including carriers) or hepatitis C virus (anti-HCV positive).
- History of alcohol addiction , drug abuse or mental disease.
- Participated in any other clinical trial within three months prior to enrollment.
- Women who are pregnant or lactating or have breeding intent within 6 months.
- The investigators believe that any increase in the risk of the subject or interference with the results of the trial.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Sperimentale: C-CAR011
In day 0, 1 and 2, CAR011 cells will be intravenous infused at the 10%, 30% and 60% ratio respectively.
|
CD19-targeted chimeric antigen receptor T cells
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Lasso di tempo |
---|---|
Dose-limiting toxicity (DLT)
Lasso di tempo: 30 days
|
30 days
|
Misure di risultato secondarie
Misura del risultato |
Lasso di tempo |
---|---|
Overall response rate (ORR)
Lasso di tempo: 8 weeks
|
8 weeks
|
Sopravvivenza globale (OS)
Lasso di tempo: 24 settimane
|
24 settimane
|
Minimal residual disease negative remission rate(MRD-)
Lasso di tempo: 8 weeks
|
8 weeks
|
Collaboratori e investigatori
Sponsor
Collaboratori
Investigatori
- Investigatore principale: Li Yu, Chinese PLA General Hospital
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Anticipato)
Completamento dello studio (Anticipato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- CBMG2016003
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su C-CAR-011
-
Cellular Biomedicine Group Ltd.The First Affiliated Hospital with Nanjing Medical UniversityCompletatoLinfoma diffuso a grandi cellule B refrattarioCina
-
CelgeneTerminatoBeta talassemia intermedia | Beta talassemia maggioreFrancia, Regno Unito, Italia, Grecia
-
Abbisko Therapeutics Co, LtdReclutamento
-
Nexel Co., Ltd.Novotech (Australia) Pty LimitedCompletato
-
Hutchison Medipharma LimitedCompletatoMalattie infiammatorie intestinali
-
AbbVieCompletatoCancro polmonare a piccole celluleStati Uniti, Giappone, Corea, Repubblica di, Taiwan
-
Orionis Biosciences IncReclutamento
-
CelgeneCelgene CorporationTerminatoTumori solidi avanzatiStati Uniti
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletatoAnemia | Mielofibrosi | Neoplasia mielodisplastica/mieloproliferativaStati Uniti
-
Fochon Pharmaceuticals, Ltd.Reclutamento